Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib in ALK Positive Non-Small Cell Lung Cancer
NCT06225427Phase 1Recruiting
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gilteritinib in non-small cell lung cancer (NSCLC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Incidence of adverse events at 30 days and Dose-limiting toxicities at 3 weeks. Started Jul 2024; status: recruiting.
02
Drugs
gilteritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06225427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225427.